Display Settings:

Format

Send to:

Choose Destination

    Mol Biochem Parasitol. 2008 May;159(1):64-8. Epub 2008 Jan 19.

    A drug-selected Plasmodium falciparum lacking the need for conventional electron transport.

    Smilkstein MJ, Forquer I, Kanazawa A, Kelly JX, Winter RW, Hinrichs DJ, Kramer DM, Riscoe MK.

    Medical Research Service, Department of Veterans Affairs Medical Center, Portland, OR 97239, USA. smilkste@ohsu.edu

    Mitochondrial electron transport is essential for survival in Plasmodium falciparum, making the cytochrome (cyt) bc(1) complex an attractive target for antimalarial drug development. Here we report that P. falciparum cultivated in the presence of a novel cyt bc(1) inhibitor underwent a fundamental transformation in biochemistry to a phenotype lacking a requirement for electron transport through the cyt bc(1) complex. Growth of the drug-selected parasite clone (SB1-A6) is robust in the presence of diverse cyt bc(1) inhibitors, although electron transport is fully inhibited by these same agents. This transformation defies expected molecular-based concepts of drug resistance, has important implications for the study of cyt bc(1) as an antimalarial drug target, and may offer a glimpse into the evolutionary future of Plasmodium.

    PMID: 18308406 [PubMed - indexed for MEDLINE]

    PMCID: PMC2396451

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Atovaquone (Mepron®)

      Atovaquone is used to treat Pneumocystis carinii pneumonia (PCP).